

Carl Danzig, M.D., FASRS

Home:
2721 NE 18th Street
Fort Lauderdale, FL 33305

Phone:
215-630-5010 (mobile)
carldanzigmd@gmail.com

Personal

Date of Birth: August 23, 1978
Place of Birth: Philadelphia, PA

Work History

- Sept. 2011 – Aug 2025 Rand Eye Institute / William J. Rand M.D, P.A. / Rand Surgical Pavilion. Ophthalmology and Director of Vitreoretinal Department. Director of Retina Clinical Research.
- Oct. 2011 – to Current: Broward Health North / Ophthalmology with Vitreoretinal sub-specialty.

Education

- Vitreoretinal Fellowship, University of Texas – Southwestern Medical Center; Dallas, TX, July 2009 – July 2011
- PGY-III/IV Ophthalmology Residency, SUNY-Downstate, Brooklyn, NY, July 2007 – June 2009, GME Citations Committee member, Social Chair, Chief Resident
- PGY-II Ophthalmology Residency, Martin Luther King, Jr. Hospital/ Charles R. Drew University, Los Angeles, CA, July 2006 – June 2007
- Research Fellowship, Department of Ocular Oncology, Wills Eye Hospital, Philadelphia, PA, July 2005 – June 2006
- PGY-I Transitional Year Internship, Crozer-Chester Medical Center, Upland, PA, Department of Medicine, Jun 2004 – Jun 2005, Medical Ethics Committee
- M.D., Temple University School of Medicine, Philadelphia, PA, Aug. 2000 – May 2004
- Summer Externship, Hospital Israelita Albert Einstein, São Paulo, Brazil, 2001
- B.A., Tulane University, New Orleans, LA, Major: Philosophy, Aug. 1996 – May 2000, Languages Spoken
- English
- Spanish-proficient

Certifications and Examinations

- American Board of Ophthalmology, Board Certified
- BLS and ACLS certified

Medical Licensures

- Florida - Active
- Texas - Active

Professional Experience

- Rand Eye Institute. Director of Vitreoretinal Services and Clinical Research. September 2011-2025
- JAMA Ophthalmology. Peer-Review Editor.
- Drugs of Today. Peer-Review Editor
- Journal of VitreoRetinal Diseases. Peer-Review Editor.
- Diabetes Care Journal. Peer-Review Editor.

Academic Appointments

Florida Atlantic University. Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine. Boca Raton, FL 2014-Present

Professional Society Memberships

- Retina Society
- American Academy of Ophthalmology
 - Editorial Board, ONE Network, Retina section (2016 -2021)
- Association for Vision Research and Ophthalmology
- American Society of Retina Specialists
 - Fellow of the American Society of Retina Specialists
- Vit-Buckle Society
- Asociacion Colombiana Retina y Vitreo

Awards

- American Society of Retina Specialists, Honor Award, 2023
- National Eye Institute Travel Grant, Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 2007

Publications

- **Danzig CJ**, Dinah C, Ghanchi F, Hattanbach LO, Khanani AM, Lai T, Shimura M, Abreu F, Arrisi P, Liu Y, Paris LP, Retiere AC, Willis JR, Schlottmann P. Faricimab Treat-and-Extend Dosing for Macular Edema due to Retina Vein Occlusion: 72-Week Results from the BALATAN and COMINO Trials. Ophthal Retina 2025 Sep;9(9):848-859.

- García-Layana A, Chi GC, Kodjikian L, Parravano M, Chow D, Jackson TL, **Danzig C**, Paris LP, Mirt M, Henry-Szatkowski M, Lewis HB, Gentile B. Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study. *Ophthalmic Res.* 2025;68(1):13-22.
- **Danzig CJ**, Khanani AM, Loewenstein A. C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. *Immunotherapy.* 2024;16(12):779-790.
- Dang S, Parke DW, Sodhi GS, Eichenbaum D, Nielsen J, **Danzig C**, Lalwani G, Moinfar N, London N, Kimura A, Jumper JM, Lord K, Sheth V, Pieramici D, Orlin A, Madson A, Horton M, Blim J, Cao JA, Thompson J, Khanna S, Wykoff CC, Shah AR. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. *JAMA Ophthalmol.* 2024 Aug 1;142(8):716-721.
- Hasan N, Mehrotra K, **Danzig CJ**, Eichenbaum DA, Ewald A, Regillo C, Momenaei B, Sheth VS, Lally DR, Chhablani J. Screen Failures in Clinical Trials in Retina. *Ophthalmol Retina.* 2024 Nov;8(11):1093-1099.
- **Danzig CJ**, Khanani AM, Kaiser PK, Chang M, Kovach JL, Lally DR, Rachitskaya A, Sheth V, Vajzovic L, Clark J, Tang J, Zhu L, Desai D, Chakravarthy U. Vision loss reduction with avacincaptad pegol for geographic atrophy: A 12-month post hoc analysis of Gather1 and Gather2 trials. *Ophthal Retina.* 2024 Nov;8(11):1052-1060.
- Tadayoni R, Paris LP, **Danzig CJ**, Abreu F, Khanani AM, Brittain C, Lai TYY, Haskova Z, Sakamoto T, Kotecha A, Schlottmann PG, Liu Y, Seres A, Retiere AC, Willis JR, Yoon YH; BALATON and COMINO Investigators. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. *Ophthalmology.* 2024 Aug;131(8):950-960.
- Khanani AM, Boyer DS, Wykoff CC, Regillo CD, Busbee BG, Pieramici D, **Danzig CJ**, Joondeph BC, Major JC Jr, Turpcu A, Kiss S. Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. *EClinicalMedicine.* 2023 Dec 22;67:102394.
- Khanani AM, Patel SS, Staurenghi G, Tadayoni R, **Danzig CJ**, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. *Lancet.* 2023 Oct 21;402(10411):1449-1458.
- Hattenbach, L.O., Abreu, F., Arrisi, P., Basu, K., **Danzig, CJ.**, Guymer, R., Haskova, Z., Heier, J.S., Kotecha, A., Liu, Y. and Loewenstein, A., Seras A., Willis J., Wykoff C., Paris LP. BALATON and COMINO: Phase 3 Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. *Ophthalmology Science.* 2023 Mar 27;3 (3) 100302.
- Ashkenazy N, **Danzig CJ**, Rong AJ, Read SP, Maeng MM, Flynn HW Jr, Albin TA. Orbital Gas after 25-Gauge Pars Plana Vitrectomy with Incorrect Gas Mixture. *Case Rep Ophthalmol.* 2023 Jul 10;14(1):301-306.
- Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Mein L, Sheth VS, Wolfe JD, Singer MA, **Danzig CJ**. The real-world efficacy

and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. *Eye (Lond)*. 2023 May 12.

- Amin KV, Hariprasad SM, **Danzig CJ**. Complement Inhibitors for the Treatment of Geographic Atrophy. *Ophthalmic Surg Lasers Imaging Retina*. 2023 Feb;54(2):66-70.
- Khan H, Aziz AA, Sulahria H, Khan H, Ahmed A, Choudhry N, Narayanan R, **Danzig C**, Khanani AM. Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. *Clin Ophthalmology*. 2023 Jan 23;17:321-327. Khanani A.M., Thomas M.J., Aziz A.A., Weng CY, **Danzig CJ**, Yiu G, Kiss S, Waheed N, Kaiser P. Review of gene therapies for age-related macular degeneration. *Eye* 2022 Feb;36 (2) 303–311.
- Khanani AM, Russell MW, Aziz AA, **Danzig CJ**, Weng CY, Eichenbaum DA, Singh RP. Angiopoietins as Potential Targets in Management of Retinal Disease. *Clin Ophthalmol*. 2021 Sep 4; 15:3747-3755.
- Khanani AM, Aziz AA, Weng CY, Lin WV, Vannavong J, Chhablani J, **Danzig CJ**, Kaiser PK. Port delivery system: a novel drug delivery platform to treat retinal diseases. *Expert Opin Drug Deliv*. 2021 Aug 24;1-6.
- **Danzig C**. Surgical management of symptomatic vitreous floaters. *Ophthalmic Surg Lasers Imaging Retina*. 2014 Nov-Dec; 45(6):1-3
- Shields CL, Say EA, Stanciu N, Bianciotto C, **Danzig CJ**, Shields JA. Cavitary choroidal metastasis from lung carcinoid tumor. Report of 3 cases. *Arch Ophthalmol*. 2011;129 (1):102-104.
- Labriola L, Shields CL, **Danzig CJ**, Eagle RC, Shields JA. Reverse magnetic resonance signal from intraocular hemorrhage. *Retinal Cases & Brief Reports*. 3(3):237-239.
- **Danzig CJ**, Shields CL, Mashayekhi A, Ehya H, Manquez M, Shields JA. Fluorescein angiography of iris juvenile xanthogranuloma. *J Pediatr Ophthalmol Strabismus*. 2008. Mar-Apr 45(2):110-2.
- Furuta M, Shields CL, **Danzig CJ**, Eagle RC, Shields JA. Ultrasound biomicroscopy of eyelid eccrine hidrocystoma. *Can J Ophthalmol*. 2007 Oct; 42 (5).
- Kobrin E, Shields CL, **Danzig CJ**, Ehya H, Shields JA. Intraocular lacrimal gland choristoma diagnosed by fine-needle aspiration biopsy. *Cornea*. 2007 Jul;26(6):753-5.
- Shields CL, Manquez ME, Ehya H, Mashayekhi A, **Danzig CJ**, Shields JA. Fine-needle aspiration biopsy of iris tumors in 100 consecutive cases: technique and complications. *Ophthalmology*. 2006 Nov; 113(11):2080-6.
- **Danzig C**, Lefkowitz T. Students Describe Their Experience [translated to Portuguese]. *Boletim: Instituto de Ensino e Pesquisa Albert Einstein*. 1:5 April – Sept 2001. Pg. 35.

Posters

- Khan, H, Nasab P, Khan H, Ali H, Gahn G, Almeida D, Barakat M, Corradetti G, **Danzig C**, Graff J, Wolfe J, Sadda S, Khanani A. Real-world Efficacy and Safety of Faricimab in Diabetic Macular Edema: First-time 2-year Results of the TAHOE study. American Society of Retina Specialists. Long Beach, CA. July 2025
- Khan H, Khan H, Aziz AA, Gahn GM, Abbey A, Barakat MR, Corradetti G, **Danzig CJ**, Graff JM, Nielson JS, Wolfe JD, Sadda SR, Khanani AM. The Real-World Efficacy and

Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study. Association for Research in Vision and Ophthalmology Meeting, Seattle WA, May 2024.

- Mojumder O, Aziz AA, Khan H, Abbey AM, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Singer MA, **Danzig CJ**, Khanani AM. Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study. Association for Research in Vision and Ophthalmology Meeting, Seattle WA, May 2024
- Khan H, Aziz AA, Mojumder O, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Singer MA, **Danzig CJ**, Khanani AM. Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study. Women in Ophthalmology Meeting, Virtual, August 2023.
- Khan H, Aziz AA, Mojumder O, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, **Danzig CJ**, Haug SJ, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Singer MA, Khanani AM. The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study. Women in Ophthalmology Meeting, Virtual, August 2023
- Somani NA, Khan H, Aziz AA, Khan H, Chang EY, Gahn GM, Mohan N, Lauer E, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Corradetti G, **Danzig CJ**, Haug SJ, Javaheri M, Liu EM, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Wong RW, Sadda SR, Singer MA, Khanani AM. Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study. American Society of Retina Specialists Meeting, Seattle, WA, July 2023.
- Eichenbaum DA, Luo C, Huang M, Zhao Y, Infante CC, Ehrlich M, Liu J, **Danzig C**. Characterizing infection risk related to systemic complement Factor D inhibition. American Society of Retina Specialists, Seattle, WA July 2023.
- Aziz AA, Khan H, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London N, Sheth VS, Wolfe J, Singer MA, **Danzig CJ**, Khanani AM. The TRUCKEE Study: Real-World Efficacy and Safety of Faricimab in Neovascular AMD. Association for Research in Vision and Ophthalmology, New Orleans, LA, Apr 2023.
- Khan H, Aziz AA, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London N, Sheth VS, Wolfe J, Singer MA, **Danzig CJ**, Khanani AM. Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study. Association for Research in Vision and Ophthalmology, New Orleans, LA, Apr 2023.
- Maturi R, Csaky KG, **Danzig CJ**, Jounssen AM, Modi Y, Sheth V, Willis JR, Haskova Z, Westenskow P. Ang-2 Signaling and Vascular Stability in Diabetic Macular Edema. American Academy of Ophthalmology. Chicago, IL. Sept/Oct 2022.

- **Danzig CJ.** Gather 1: A Subgroup Analysis of Baseline Patient Characteristics and Mean Growth Rate in GA area. World Ophthalmology Congress. Sept 2022 (virtual).
- **Danzig CJ,** Khanani AM, Eichenbaum DA, Wykoff CC, Hsu J, Lally DR, Sheth V, Heier JS, Patel SS, Nielsen JS. Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates a Continued Reduction in the Mean Rate of Geographic Atrophy Growth: 18-Month Results from the Gather1 Clinical Trial. American Academy of Ophthalmology, New Orleans, LA Nov 2021.
- **Danzig CJ,** Blotner S, Steffen V, Haskova Z. Clinical Trial vs Real-World Outcomes with Anti-VEGF Therapy for Branch and Central Retina Vein Occlusion. Association for Research in Vision and Ophthalmology, San Francisco, CA May 2021 (virtual).
- London N, Khanani AM, Thompson MM, **Danzig CJ,** Kulkarni AD, Sheth VS, Jhaveri CD, Eichenbaum DA, Singer MA. Treating Neovascular AMD Patients with Brolucizumab: A Real-World Study. American Society of Retina Specialists Meeting, Seattle, WA July 2020 (virtual).
- **Danzig C,** Quezada Ruiz C, Basu K, Grzeschik S, Sahni J, Silverman D, Osborne A, Haskova Z. Efficacy and Safety of Faricimab Every 16 or 12 Weeks for Neovascular Age-Related Macular Degeneration: STAIRWAY Phase 2 Results. Association for Research in Vision and Ophthalmology, Vancouver, Canada, April 2019.
- **Danzig CJ,** Ehrenhaus M, Lui H, Lazzaro D, Kumar AV, A case of a 9 Year-Old Male with Bilateral Concomitant Keratoconus and Posterior Lenticonus. Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, April 2008.
- **Danzig C,** Mashayekhi A, Shields CL, Shields JA. Fluorescein Angiography of Pediatric Iris Tumors and Pseudotumors. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 2007.
- Manquez M, Mashayekhi A, Ehya H, Eagle R, **Danzig C,** Shields J. Fine Needle Aspiration Biopsy for Iris Tumors. American Academy of Ophthalmology, New Orleans, LA, October 2004.
- Alley C, **Danzig C,** Membrano J, Gaughan J, Baldassano V. Comparison of Axial Lengths and Intraocular Lens Implant Powers among Populations from Urban United States, Nicaragua, Dominican Republic, and Vietnam. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, May 2003.

Podium/Paper Presentations/Panels

- **Danzig CJ,** Aziz AA, Khan H, Ali H, Gahn G, Almeida D, Barakat MB, Chang EY, Corradetti G, Graff JM, Wolfe JD, Sadda SR, Khanani AK. The TAHOE Study: Real World Efficacy and Safety of Faricimab in DME – 2.5 Year Results. The Retina Society, Chicago, IL. Sept 2025.
- Suner I, Bhatt HK, **Danzig CJ,** Dinah C, Dagincourt N, Pereira LP, Schweitzer, Tommen J. Association of Early Macular Leakage Resolution with Extended Dosing Intervals in Patients with RVO: A BALATON/COMINO Post Hoc Analysis. The Retina Society. Chicago, IL. Sept 2025.

- Sheth V, Aziz A, Khan H, Abbey A, Almeida D, Banda H, Avery R, Barakat M, Bhandari R, Chang E, Corradetti G, **Danzig C**, Graff J, Haug S, Javaheri M, Liu E, London N, Wolfe J, Wong R, Sadda S, Singer M, Khanani AM. Real-world Efficacy and Safety of Faricimab in Neovascular Age-related Macular Degeneration: 3.5-year Results of the TRUCKEE Study. The Retina Society. Chicago, IL. Sept 2025.
- Dinah C, **Danzig CJ**, Bhatt HK, Dagincourt N, Pereira LP, Schweitzer J, Tommen J. Association of Early Macular Leakage Resolution with Extended Dosing Intervals in Patients with RVO: A BALATON/COMINO Post Hoc Analysis. EURETINA Congress. Paris, France Sep 2025
- **Danzig C**, Bhatt H, Dagincourt N, Pereira L, Schweitzer J, Tommen J. Association of Early Macular Leakage Resolution with Extended Dosing Intervals in Patients with RVO: A BALATON/COMINO Post Hoc Analysis. American Society of Retina Specialists. Long Beach, CA. July 2025 (Paper On-Demand)
- Modi Y, Almeida D, Khanani A, **Danzig C**, Ribeiro R. VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema. American Society of Retina Specialists. Long Beach, CA. July 2025
- Khanani A, Aziz A, Khan H, Abbey A, Almeida D, Banda H, Avery R, Barakat M, Bhandari R, Chang E, Corradetti G, **Danzig C**, Graff J, Haug S, Javaheri M, Liu E, London N, Sheth V, Wolfe J, Wong R, Sadda S, Singer M. Real-world Efficacy and Safety of Faricimab in Neovascular Age-related Macular Degeneration: First-time 3.5-year Results of the TRUCKEE Study. American Society of Retina Specialists. Long Beach, CA. July 2025 (Paper On-Demand)
- **Danzig CJ**. ASPIRE Phase 2b Trial: Senolytic UBX 1325 (foselutoclax) Head-to-Head against Aflibercept in Diabetic Macular Edema. Clinical Trials at the Summit. Las Vegas, NV. June 2025.
- **Danzig CJ**, Hu A, Khanani AM, Marcus D, Barakat M, Sheth V, Berger B, Singer M, Wykoff C, Brown D. Volumetric Macular Fluid Analysis of the Impact of a Single Axitinib Intravitreal Injection (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy. Retina World Congress. Fort Lauderdale, FL May 2025.
- **Danzig CJ**, Khanani AM, Boyer DS, Nguyen QD, Markabi S. BCVA and CST Improvement over 12 weeks with OCS-01 Eye Drops in DME from DIAMOND-Stage 1 trial. Association for Research in Vision and Ophthalmology. Salt Lake City. May 2025
- Khanani AM, Aziz AA, Khan H, Abbey AM, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Graff JM, Haug SJ, Javaheri M, Liu EM, London NJS, Nielson JS, Sheth VS, Wolfe JD, Wong RW, Sadda SVR, Singer M. Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: First-time 3-year Results of the TRUCKEE Study. Angiogenesis, Exudation, and Degeneration 2024. Miami, FL Feb 2025. (virtual).
- **Danzig C**. OTX-TKI from Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMD. Angiogenesis, Exudation, and Degeneration 2024. Miami, FL Feb 2025. (virtual).

- Makkouk F, Hu A, Khanani AM, Alam S, **Danzig C**, Hershberger VS, Maturi RK, Murtaza A, Edwards AO, Eichenbaum D, Emanuelli A, Gonzalez V, Heier J, Kay C, Pearlman J, Pieramici D, Sheth V, Wells J, Somayeh H, Chung C, Kirn D, Kim R. Interim Results from the Population Extension Cohort in the Phase 2 PRISM Clinical: Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-related Macular Degeneration. Royal Hawaiian Eye, Retina Meeting. Kauai, HI Jan 2025.
- Kupperman BD, **Danzig CJ**, Vajzovic L, Khanani AM, Luo D, Luo D, Ceron O. Reduction in Risk Probability in Persistent Vision Loss with Avacincaptad Pegol in Geographic Atrophy: 2-year Results from the GATHER2 Trial. FLORetina ICOOR 2024. Florence Italy Dec 2024.
- Graff J, Aziz AA, Khan H, Graff T, Abbey AM, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti C, **Danzig CJ**, Haug SJ, Javaheri M, Liu EM, London N, Nielson, Sheth VS, Wolfe JD, Wong RW, Sadda SR, Singer MA, Khanani AM. Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: Two Year Results of the TRUCKEE Study. EURETINA Congress. Barcelona, Spain. Sept 2024.
- Almeida D, Khan H, Aziz AA, Gahn G, Barakat MR, Corradetti C, **Danzig CJ**, Graff J, Nielson JS, Wolfe JD, Khanani AM. The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: First Time One Year Results of the TAHOE Study. EURETINA Congress. Barcelona, Spain. Sept 2024.
- **Danzig CJ**. Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the Phase 3 BALATON and COMINO Trials. American Society of Retina Specialists. Stockholm, Sweden. July 2024.
- **Danzig CJ**. 24-week Results from the Randomized Phase 2 Dose Expansion Stage of the PRISM Trial Evaluating 4D-150 in High Need nAMD Patients: Injection-free Patient Analyses. Clinical Trials at the Summit. Park City, UT June 2024
- **Danzig CJ**. Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the Phase 3 BALATON and COMINO Trials. Retina World Congress. Fort Lauderdale, FL May 2024
- Aziz AA, Khan H, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Graff JM, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Wong RW, Sadda, SR, Singer MA, Khanani AM. The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration; The TRUCKEE Study – 2 Year Results. Association for Research in Vision and Ophthalmology Meeting, Seattle WA, May 2024.
- **Danzig CJ**. AVD-104 for geographic atrophy: Glyco-immunologic modulation of macrophage activity. Angiogenesis, Exudation, and Degeneration 2024. Miami, FL Feb 2024. (virtual).
- Khanani AM, Aziz AA, Khan H, Lauer E, Khan H, Abbey AM, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Graff J, Haug SJ, Jhaveri M, Liu E, London N, Nielson J, Sheth VS, Wolfe JM, Wong R, Sadda SR, Singer M, Mohan N.

Insight from clinical practice—First year experience of faricimab in the real world. Angiogenesis, Exudation, and Degeneration 2024. Miami, FL Feb 2024. (virtual).

- Vajzovic L, Khanani AM, Patel SS, Staurengi G, Tadayoni R, **Danzig CJ**, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielson JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ. The efficacy and safety of avacincaptad pegol in geographic atrophy: 24-month results from GATHER2. FLORetina/ICOOR, Rome, Italy, Dec 2023.
- Singer M, Khan H, Aziz AA, Khan H, Gahn GM, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Graff JM, Haug SJ, Javaheri M, Liu EM, London NJS, Nezgoda J, Sadda, SR, Sheth VS, Singer MA, Wolfe JD, Wong RW, Khanani AM. Real-World Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study. Asia-Pacific Vitreo-Retina Society, Hong Kong, China, December 2023.
- Singer M, Khan H, Aziz AA, Khan H, Gahn GM, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Graff J, Haug SJ, Javaheri M, Liu EM, London NJS, Nezgoda J, Sadda, SR, Sheth VS, Singer M, Wolfe JD, Wong RW, Khanani AM. The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study. Asia-Pacific Vitreo-Retina Society, Hong Kong, China, December 2023.
- Khanani AM, Patel SS, Staurengi G, Tadayoni R, **Danzig CJ**, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Mones J, Nielson JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ. Gather2: Two-Year Data. American Academy of Ophthalmology. Retina Subspecialty Day. San Francisco, CA, Nov 2023.
- Majcher C, **Danzig CJ**, Khanani AM, Lally DR, Vajzovic L, Rachitskaya A, Chang M, Kovach J, Sheth VS. Avacincaptad pegol for geographic atrophy: pooled, post hoc analysis of vision loss from the GATHER trials. American Academy of Optometry. New Orleans, LA, Oct 2023.
- Kuppermann BD, Chakravarthy U, Kaiser PK, Heier JS, Khanani AM, Vajzovic L, Chang M, Weng CY, Sheth VS, **Danzig CJ**, Lally DR, Clark J, Zhu L, Tang J, Desai D. VA and LLVA in eyes with geographic atrophy: a post hoc analysis of GATHER1 and GATHER2. Retina Society. New York, NY Oct 2023.
- Chang M, **Danzig CJ**, Eichenbaum DA, Fortun J, Khanani AM, Kovach JL, Clark J, Zhu L, Tang J, Desai D. Relationship between vision and loss and vision-related QoL in participants with geographic atrophy in GATHER1 and GATHER2. Retina Society. New York, NY Oct 2023.
- Vajzovic L, Khanani AM, Patel SS, **Danzig CJ**, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Nielsen JS, Sheth VS, Kaiser PK. Treatment response to avacincaptad pegol: a subgroup analysis of GATHER1 and GATHER2. EURETINA Congress. Amsterdam, The Netherlands, Oct 2023.
- Chakravarthy U, Kaiser PK, Heier JS, Khanani AM, Vajzovic L, Chang M, Weng CY, Sheth VS, **Danzig CJ**, Lally DR, Clark J, Zhu L, Tang J, Desai D. Reduction in vision loss in patients with geographic atrophy treated with avacinacptad pegol: an exploratory post hoc

analysis of GATHER1 and GATHER2. EURETINA Congress. Amsterdam, The Netherlands, Oct 2023.

- Almeida DRP, Aziz AA, Khan H, Somani NA, Khan H, Gahn GM, Mohan N, Lauer E, Abbey AM, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Haug SJ, Javaheri M, Liu EM, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Wong RW, Sadda SR, Singer MA, Khanani AM. The TRUCKEE Study: Real World Efficacy and Safety of Faricimab in Neovascular AMD. EURETINA Congress, Amsterdam, Netherlands, October 2023.
- Nielson JS, Khan H, Aziz AA, Khan H, Gahn GM, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Corradetti G, **Danzig CJ**, Graff J, Haug SJ, Javaheri M, Liu EM, London NJS, Nezgoda J, Sadda, SR, Sheth VS, Singer M, Wolfe JD, Wong RW, Khanani AM. Real World Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study. EURETINA Congress, Amsterdam, Netherlands, October 2023.
- **Danzig CJ**, Kaiser P, Lally D, Jaffe GJ, Khanani AM, Wykoff CC, Heier JS, Tang J, Zhu L, Clark J, Desai D. Intravitreal avacincaptad pegol in geographic atrophy: Post-hoc analysis of vision loss in the GATHER clinical trial program. American Society of Retina Specialists, Seattle, WA July 2023.
- Chang EY, Khan H, Aziz AA, Gupta A, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Wolfe JM, **Danzig CJ**, Haug SJ, London N, Sheth VS, Singer MA, Khanani AM. The TRUCKEE Study: Real world efficacy and safety of faricimab in neovascular AMD. American Society of Retina Specialists, Seattle, WA July 2023.
- **Danzig CJ**, Kaiser P, Lally D, Jaffe GJ, Khanani AM, Wykoff CC, Heier JS, Tang J, Zhu L, Clark J. Intravitreal avacincaptad pegol in geographic atrophy: Post-hoc analysis of vision loss in the GATHER clinical trial program. Clinical Trials at the Summit, Park City, UT, June 2023.
- Avery RL, Khan H, Aziz AA, Almeida DRP, Banda HK, Barakat MR, Bhandari R, Chang EY, **Danzig CJ**, Haug SJ, London NJS, Nielsen JS, Sheth VS, Wolfe JD, Singer MA, Khanani AM. The TRUCKEE Study: Real World Efficacy and Safety of Faricimab in Neovascular AMD. Clinical Trials at the Summit, Park City, UT, June 2023.
- **Danzig CJ**, Kaiser P, Lally D, Jaffe GJ, Khanani AM, Wykoff CC, Heier JS, Tang J, Zhu L, Clark J; Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study. Association for Research in Vision and Ophthalmology, New Orleans, LA, Apr 2023.
- Singer MA, Khan H, Aziz AA, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, **Danzig CJ**, Haug SJ, London NJS, Sheth VS, Wolfe JD, Khanani AM. The TRUCKEE Study: Real World Efficacy and Safety of Faricimab in Neovascular AMD. Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, February 2023.
- Singer MA, Khan H, Aziz AA, Gupta A, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, **Danzig CJ**, Haug SJ, London NJS,

Singer MA, Sheth VS, Wolfe JD, Khanani AM. The TRUCKEE Study: Real World Efficacy and Safety of Faricimab in Neovascular AMD. Congress of the Asia-Pacific Vitreo-Retina Society Meeting, Taipei, Taiwan, November 2022

- Khurana, R, Wells JA, Bauman C, **Danzig C**, Murata T, Schottmann P, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z. Efficacy, durability, and safety of faricimab in DME: 2-year results from YOSEMITE and RHINE. Retina Society. Pasadena, CA. Nov 2022.
- Wolfe JM, Khan H, Aziz AA, Gupta A, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, **Danzig CJ**, Haug SJ, London N, Sheth VS, Singer MA, Khanani AM. The TRUCKEE Study: Real world efficacy and safety of faricimab in neovascular AMD. Retina Society. Pasadena, CA. Nov 2022.
- Khanani AM, Patel SS, Staurenghi G, Tadayoni R, **Danzig CJ**, Lally DR, Loewenstein A, Boyer DS, Regillo CD, Wong TP, Jaffe GJ, Tang J, Zhu L, Patel H, Clark J. Gather2 Pivotal Phase 3 Study Results: Efficacy of intravitreal avacincaptad pegol in geographic atrophy. American Academy of Ophthalmology. Retina Subspecialty Day. Chicago, IL. Sept/Oct 2022.
- Bauman C, Wells JA, **Danzig C**, Eichenbaum DA, Lim JI, Schottmann P, Singh R, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z. Efficacy, durability, and safety of faricimab in DME: 2-year results from YOSEMITE and RHINE. American Academy of Ophthalmology. Chicago, IL. Sept/Oct 2022.
- Bhandari R, Khan H, Aziz AA, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Chang EY, **Danzig CJ**, Haug SJ, London N, Sheth VS, Singer MA, Wolfe JM, Khanani AM. The TRUCKEE Study: Real world efficacy and safety of faricimab in neovascular AMD. American Academy of Ophthalmology. Retina Subspecialty Day. Chicago, IL. Sept/Oct 2022.
- Murata T, Wells JA, Bauman C, **Danzig CJ**, Schlottmann P, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z. Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results from the Phase 3 YOSEMITE AND RHINE Trials. World Ophthalmology Congress. Sept 2022. (virtual)
- Mehta H, **Danzig C**, Paris L, Lin H, Jain N, Abreau F, Haskova Z, Hattenbach L. Faricimab for Macular Edema Due to Retina Vein Occlusion: Rationale and Design of the Phase 3 BALATON and COMINO Trials. World Ophthalmology Congress. Sept 2022 (virtual).
- Bauman C, **Danzig C**, Blotner S, Steffen V, Haskova Z. Clinical Trial versus Real-World Outcomes with Anti-VEGF Therapy for Branch and Central Retina Vein Occlusion. EURETINA Congress. Hamburg, Germany. Sept 2022.
- Sheth VS, Khan H, Aziz AA, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, **Danzig CJ**, Haug SJ, London N, Singer MA, Wolfe JM, Khanani AM. The TRUCKEE Study: Real world efficacy and safety of faricimab in neovascular AMD. EURETINA Congress. Hamburg, Germany. Sept 2022.
- **Danzig CJ**, Khan H, Aziz AA, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Sheth VS, Singer MA, Wolfe JM,

Khanani AM. The TRUCKEE Study: Real World Efficacy and Safety of Faricimab in Neovascular AMD. American Society of Retina Specialists, New York, NY July 2022.

- **Danzig CJ**, Olson J, Kaiser P, Heier J, Khanani A, Bhandari R. Biocompatibility and Affinity of RO-634, a Novel Bispecific Protein. American Society of Retina Specialists, New York, NY July 2022. (Paper On-Demand)
- Dang S, Parke DW, Sodhi G, Eichenbaum D, Nielson J, **Danzig C**, Lalwani G, Moinfar N, London N, Kimura A, Jumper JM, Lord R, Sheth V, Pieramici D, Orlin A, Thompson J, Wykoff C. Anti-VEGF injection prior authorization impacts on retina practices. American Society of Retina Specialists, New York, NY July 2022
- Eichenbaum DA, Wells JA, Lim JI, **Danzig CJ**, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. 2-Year results from the phase 3 YOSEMITE AND RHINE trials: Efficacy, durability, and safety of faricimab in diabetic macular edema. American Society of Retina Specialists, New York, NY July 2022
- Lally DR, Heier JS, Sadda S, Eichenbaum DA, **Danzig C**. Progression of atrophy in AMD: Post hoc analysis from the GATHER1 study. American Society of Retina Specialists, New York, NY July 2022
- Bauman CR, Wells JA, **Danzig CJ**, Eichenbaum DA, Lim JI, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. 2-Year results from the phase 3 YOSEMITE AND RHINE trials: Efficacy, durability, and safety of faricimab in diabetic macular edema. Macula Society. Berlin, Germany. June 2022
- **Danzig CJ**, Wells JA, Eichenbaum DA, Lim JI, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. 2-Year results from the phase 3 YOSEMITE AND RHINE trials: Efficacy, durability, and safety of faricimab in diabetic macular edema. American Diabetic Association. New Orleans, LA June 2022
- Lim JI, Wells JA, Eichenbaum DA, **Danzig C**, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. 2-Year results from the phase 3 YOSEMITE AND RHINE trials: Efficacy, durability, and safety of faricimab in diabetic macular edema. American Ophthalmological Society, Colorado Springs, CO May 2022
- **Danzig CJ**. Starting and Managing a Successful Clinical Research Department. Clinical Trials at the Summit. Lake Tahoe, NV. May 2022
- **Danzig CJ**, Csaky KG, Modi Y, Sheth V, Willis JR, Haskova Z, Westenskow P. Angiopoietin-2 Signaling and Vascular Stability in Diabetic Macular Edema. Retina World Congress. Fort Lauderdale, FL. May 2022
- Singh RP, Wells JA, Bauman CR, **Danzig CJ**, Eichenbaum DA, Lim JI, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials. Retina World Congress. Fort Lauderdale, FL. May 2022
- Lim JI, Wells JA, Eichenbaum DA, **Danzig C**, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. Efficacy, durability, and safety of faricimab in diabetic macular edema: 2-year results from the phase 3 YOSEMITE and RHINE trials. Association for Research in Vision and Ophthalmology, Denver, CO May 2022

- **Danzig CJ**, Patient Characteristics from a post-hoc Analysis of Nascent Geographic Atrophy Progression Following Treatment with Avacincaptad Pegol from the GATHER1 Study. Association for Research in Vision and Ophthalmology, Denver, CO May 2022.
- **Danzig CJ**, Blotner S, Steffen V, Haskova Z. Clinical Trial versus Real-World Outcomes with Anti-VEGF Therapy for Branch and Central Retina Vein Occlusion. American Society of Retina Specialists. San Antonio, TX. Oct 2021.
- Heier, JS, **Danzig CJ**, London N, Eichenbaum DA, Sheth VS, Singer M, Dhoot D. Establishing a Successful Clinical Research Department: The Real Deal. Clinical Trials at the Summit. Lake Tahoe, NV. August 28, 2021 (virtual)
- **Danzig CJ**. Wet AMD Update: What's New in the World of Clinical Trials. Masters of Ophthalmology. Florida Society of Ophthalmology. Palm Beach, FL. July 10, 2021
- Aziz AA, Khanani AM, London N, Hagen MM, **Danzig CJ**, Kulkarni AD, Sheth VS, Jhaveri CD, Eichenbaum DA, Singer M. Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: The REBEL Study. Association for Research in Vision and Ophthalmology, San Francisco, CA May 2021 (virtual)
- Busbee B, Boyer DS, Khanani AM, Wykoff CC, Pieramici DJ, Regillo C, **Danzig CJ**, Joondeph BC, Major J, Hoang C, Turpcu A, Chung C, Kiss S, Gasmi M, Osbourne A. Phase 1 Study of Intravitreal Gene Therapy with ADVIM-022 for Neovascular AMD (OPTIC Trial). Association for Research in Vision and Ophthalmology, San Francisco, CA May 2021 (virtual)
- **Danzig C**, Lin H, Guibord P, Silverman D, Quezada Ruiz C, Stoilov I, Haskova Z; Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial. American Society of Retina Specialists Meeting, Seattle, WA. July 26, 2020 (virtual)
- **Danzig C**, Lin H, Guibord P, Silverman D, Quezada Ruiz C, Stoilov I, Haskova Z; Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial. Association for Research in Vision and Ophthalmology, Baltimore, MD. May 2020 (virtual)
- **Danzig C**. Efficacy and Safety of Faricimab Every 16 or 12 Weeks for Neovascular Age-Related Macular Degeneration: STAIRWAY Phase 2 Results. Masters in Ophthalmology. Florida Society of Ophthalmology. Hollywood, FL. June 29, 2019
- **Danzig, C**. Starting Clinical Trials in Private Practice. Retina World Congress. Fort Lauderdale, FL February 23, 2019
- Manquez ME, Shields CL, Mashayekhi A, Ehya H, Eagle R Jr, **Danzig C**, Shields JA. Fine-needle aspiration biopsy of iris tumors. International Congress of Ocular Oncology, Whistler, Canada. September 2005.
- Carmack B, **Danzig C**, Pavan PR, Absorption of 689 nm Verteporfin Photodynamic Therapy Laser by Blood in vitro. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, April 2004.

Moderator for Presentations

- **Danzig CJ**, Chhablani J. Dry Macular Degeneration. Retine World Congress. Fort Lauderdale, FL. May 2025

Other Presentations/Instructional Course

- **Danzig CJ**. (Multiple presentations). Asociacion Colombiana de Retina y Vitreo (ACOREV). Cartagena, Colombia. Mar 2025
- **Danzig CJ**. (Multiple presentations). New Orleans Academy of Ophthalmology. New Orleans, LA. Feb 2025.
- **Danzig CJ**, Lally DR, Khanani AM, Kaiser PK, Vazjovic L. GA: Where Are We Now, and Where Are We Heading? The Changing Landscape of Treatment. American Academy of Ophthalmology. Chicago, IL. Oct 2024. Instructional Course.
- **Danzig CJ**, Lally DR, Khanani AM, Kaiser PK. New Horizons in GA: Preparation for New Discussion with Your Dry AMD Patients. American Academy of Ophthalmology. San Francisco, CA. Oct 2023. Instructional Course.
- **Danzig CJ**, Lally DR, Khanani AM, Kaiser PK. New Horizons in GA: Preparation for New Discussion with Your Dry AMD Patients. American Academy of Ophthalmology. Chicago, IL. Sept/Oct 2022. Instructional Course.
- Khanani AM, Wycoff CC, **Danzig CJ**. Implementing Clinical Trials in a Retina Practice: How to Get Started and Recruit Successfully. American Society of Retina Specialist. Boston, MA. Aug 2017 (course on-demand).
- Rand Eye Institute: Continuing Education Seminar Series for Optometry. Individual titles available upon request, Deerfield Beach, FL, September 2011-Present
- Palm Beach County Optometric Association: You're going to do what?!?!? Boca Raton, FL, April 2012
- Wills Oncology Fellows Association, American Academy of Ophthalmology, San Francisco, CA, October 2009, Recurrence or Treatment-related Adverse Effect? Serous Retina Detachment in a Patient Previously Treated with Iodine-125 for Choroidal Melanoma.
- Wills Eye Hospital Annual Retina Club Meeting, Philadelphia, PA, October 2005, Danzig CJ. Retina astrocytic hamartoma vs. arrested retinoblastoma in 34-month-old male.

Clinical Trial Committees

- Oculis Steering Committee: (DIAMOND-1, DIAMOND-2)
- Ocular Therapeutix Steering Committee (SOL-1 and SOL-R)
- Genentech Safety Advisory Board: IL-6 program
- IvericBio Steering Committee (GATHER2)

International Grand Rounds

- University of Cape Town; Cape Town, South Africa, February 23, 2009
- Asociación para Evitar la Ceguera, Mexico City, Mexico, May 18, 2007

Carl Danzig, MD

Carl Danzig, MD

15 Sep 2025

Date